Novel Treatments for Ocular Conditions

Synakis is a pre-clinical biotech startup developing novel biomaterial-based treatments for ocular injuries and diseases, including retinal detachment, glaucoma, and age-related macular degeneration. Our mission is to restore vision and improve the lives of patients suffering from these conditions.

Synakis’ core technology, SNK-125, is a novel hydrogel specifically designed for ocular delivery. SNK-125 is injectable, biocompatible, biodegradable, non-swelling and transparent. We are developing it as a vitreous substitute for retinal surgery and to deliver engineered therapeutics to treat leading causes of blindness.

Recent Updates